In my opinion, Peyronie's disease is aberrant wound healing in response to an inflammation trapped within the layers of tunica albuginea. The arrangement of the vessels traversing the tunica albuginea is unique in that a cuff of loose areolar tissue cushions the arteries while the veins are in direct contact with the fibrous tunica. As a result, the arterial flow into the erectile tissue continues during erection (except in the rigid phase when the intracavernous pressure exceeds the systolic blood pressure) while the venous channels are compressed. When a blunt trauma breaks the fibers of the tunica with extravasation, the resulting inflammatory response creates an area of edema and cell infiltration which compress the nearby venous channels and forming a 'trapped' inflammatory response. While the secretions from leukocytes and macrophages such as elastases break the elastic fibers, the cytokines such as transforming growth factor beta (TGFb) released by the same cells stimulate production of intercellular matrix and collagen fibers. Meanwhile, because the inflammation is trapped, TGFb and other cytokines cannot be dispersed and degraded, they stimulate the production of more TGFb, which in turn produces more matrix and collagen. In our cultured Peyronie's fibroblasts, but to a much lesser degree on normal tunical fibroblasts, we also found that TGFb stimulates the production of monocyte chemotaxic protein 1 (MCP-1) and connective tissue growth factor (CTGF). MCP-1 would attract more monocytes to the area and CTGF would produce more fibrosis. Rajfer et al. recently performed microarray gene profiles and showed that osteoblast stimulating factor 1 was upregulated in Peyronie's plaque, which explains the reported incidence of calcification in up to 1 3 of patients with Peyronie's disease. All of the above 'aberrations' can be attributed to the unique anatomy of the tunica albuginea where the densely packed tunical layers trapped the inflammatory process, the venous outflow channels are compressed by the focal area of edema and cell infiltration while the immigration of leukocytes and macrophages continues because the arterial flow is not impeded. The unique ability of TGFb to produce more of itself forms a vicious cycle within this microenvironment and results in excessive production of intercellular matrix and collagen fibers. 1 The final outcome is a prolonged inflammatory response with total breakdown of the delicately arranged network of collagen and elastic fibers and excessive production of collagen fibers. In the early stage, the inflammatory process and irritation of the nerves may produce pain with or without erection. In most instances, the pain will subside either due to maturity of the inflammatory reaction or the death of the trapped nerve fibers. In chronic phase, if the fibrosis has begun to encroach upon the erectile tissue, erectile dysfunction may occur. These phenomena may contribute to the clinical presentation of Peyronie's disease in which the early phase triad consists of pain, plaque and penile deformity and the late triad consists of plaque, penile deformity and erectile dysfunction.
Strategies for combating Peyronie's disease Treatment for the inflammatory phase
If one agrees with the hypothesis of 'trapped inflammation' as the main feature of the early phase, the following 'treatment' options may make some sense:
(1) A device to mince and aspirate the inflammatory product under sonographic control. This procedure should also create a 'mouth' large enough to allow a secondary wound healing of the cavity. (2) Alternatively, after the inflammatory product has been evacuated, an acellular matrix-like substance can be injected into the cavity to allow an orderly deposition of collage and elastic fibers as well as ground substance. 6,7 (3) A microwave device, a high energy ultrasound or a shock wave device can be used to direct the energy to 'ground zero' to zap the inflammatory reaction without zapping the adjacent erectile tissue such as in the case of irradiation therapy of the plaque. (4) A strong anti-proliferatory agent such as colchicine can be injected into 'ground zero' to stop the proliferation of inflammatory cells. 8 (5) An anti-chemotactic agent can be injected into 'ground zero' to discourage the immigration of inflammatory cells. (6) An anti-cytokine agent such as anti-TGFb in the form of receptor blocker, inactive analog or antibody (eg decorin). 9,10 (7) An angiogenesis factor can be injected into 'ground zero' to induce the formation of new vessels, hopefully both arterial and venous, so that the plaque can be 'un-trapped'. 11 (8) An effective antioxidant to protect the cells from the harmful effect of oxidation injury. (9) Local injection of antifibrotic agent such as verapamil proposed by Levine to modify the process. 12 Treatment for the fibrotic phase Fibrotic or calcified 'plaque' in the center and scattered inflammatory cells and deranged collagen and elastic fibers in the periphery characterize this phase.
(1) Local injection of collagenase or other metalloproteinases with or without vacuum erection device to stretch the contracted tunica and the shortened neurovascular bundles. 13 (2) Local injection of ground substance or acellular matrix to induce orderly deposition of collagen and elastic fibers and thus improve elasticity of the tunica albuginea.
Although Peyronie's disease affects up to 3% of adult men 14 and may cause severe emotional distress and sexual dysfunction, the lack of research in this field is appalling. Since it is not life threatening or infectious, Peyronie's disease is unlikely to be considered a priority by research funding agencies or foundations. Urologists are left with no research funding, no institutional support and no patient advocates in helping the fight against the disease. Nevertheless, armed with our scientific curiosity, innovative mind and sincerity to serve our patients, I believe we will eventually prevail in the fight against Peyronie's disease.
